Last updated: February 20, 2026
What is NDC 70677-1148?
NDC 70677-1148 refers to Skytrofa (lonapegsomatropin-tcgd), a long-acting human growth hormone treatment approved by the FDA in December 2020. It is used for pediatric growth failure due to growth hormone deficiency.
Market Overview
Indications and Patient Population
- Primary indication: Pediatric growth hormone deficiency.
- Market size: Estimated at approximately 20,000 to 25,000 eligible pediatric patients in the U.S. (IQVIA, 2022).
- Competitive landscape: Competes with daily recombinant human growth hormone products, including Genotropin, Norditropin, and Saizen.
Key Differentiator
- Long-acting formulation: Approved for once-weekly injections, which could improve adherence versus daily options.
Adoption Drivers
- Efficacy and safety profile comparable to daily injectables.
- Patient preference for less frequent dosing.
- Physician willingness to transition eligible patients to long-acting formulations.
Challenges
- Cost and reimbursement hurdles.
- Limited clinical experience as a new entrant.
- Pricing sensitivity in pediatric growth management.
Price Dynamics
Current Pricing (as of 2023)
- Average Wholesale Price (AWP): Estimated at roughly $290,000 annually for a typical pediatric dose for Skytrofa.
- Comparative pricing: Daily growth hormones range from $150,000 to $250,000 annually—Skytrofa's higher price reflects the convenience of weekly dosing.
Reimbursement Environment
- Payers scrutinize cost-effectiveness.
- Commercial insurance often negotiates discounts, reducing the net price.
- Medicaid and Medicare programs have specific reimbursement policies limiting markup.
Market Penetration and Revenue
- Initial launch likely to target specialized pediatric endocrinology clinics.
- Market penetration: Expected to be modest in year 1, increasing to 20-30% of eligible patients by year 3, based on adoption trends of similar long-acting products (EvaluatePharma, 2022).
Price Projection (2024-2028)
| Year |
Estimated Average Price |
Key Factors |
| 2024 |
$290,000 |
Launch effects, limited awareness |
| 2025 |
$280,000 |
Payer negotiations, competitive pricing adjustments |
| 2026 |
$275,000 |
Increased market share |
| 2027 |
$270,000 |
Volume effects, long-term contracts |
| 2028 |
$265,000 |
Cost reductions, market saturation |
The price decline is primarily driven by increased competition, payer pressure, and volume effects, with the goal of maintaining market share amid pricing pressures.
Market Outlook
Sales Projections
- 2023: Approximately $50 million in sales (initial launch year).
- 2025: Projected to reach $150 million.
- 2028: Potentially exceeding $250 million, assuming steady adoption.
Growth Drivers
- Increasing acceptance of long-acting growth hormones.
- Expanding indications to include adult growth hormone deficiency in the future.
- The emergence of biosimilar and alternative long-acting formulations.
Risks
- New entrants with similar or superior efficacy.
- Regulatory or reimbursement changes.
- Clinical concerns over long-term safety.
Regulatory and Policy Factors
- Pending post-marketing surveillance data.
- Potential for expanded indications (e.g., adult growth hormone deficiency).
- Payer policies influenced by comparative efficacy and cost.
Key Takeaways
- The current price of Skytrofa averages around $290,000 annually.
- Market penetration expected to grow steadily, with prices declining marginally over time.
- Volume growth driven by patient preference for less frequent injections.
- Competition, reimbursement, and clinical acceptability are critical factors influencing future market dynamics.
FAQs
1. How does the price of Skytrofa compare to daily growth hormone treatments?
Skytrofa's wholesale price is about $290,000 per year, higher than daily options, which range from $150,000 to $250,000.
2. What factors could influence future price trends?
Competitive dynamics, payer negotiations, market penetration, and clinical data will shape pricing strategies.
3. What is the target patient population size in the U.S.?
Approximately 20,000 to 25,000 pediatric patients with growth hormone deficiency.
4. How quickly is Skytrofa expected to gain market share?
Likely modest initially, reaching 20-30% within three years, based on adoption patterns of similar products.
5. Are there plans for expanding indications?
Potential future expansion to adult growth hormone deficiency and other off-label uses is under consideration.
References
[1] IQVIA. (2022). Market analysis report on pediatric growth hormone therapies.
[2] EvaluatePharma. (2022). Long-acting growth hormone market projections.
